Physician profile
Benjamin Simms Cloyd
NPI 1356848428
$4,541.82
in general payments reported to CMS, 2019-2025
29 companies · $1,576 in 2025
The $1,576 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.01 · 2022: $162 · 2023: $1,397 · 2024: $1,395 · 2025: $1,576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,366.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $896.32 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $541.89 | 2023-2025 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $342.33 | 2023-2025 | Repatha, Evenity, Otezla |
| Pfizer INC. | $279.80 | 2023-2025 | |
| Glaxosmithkline, LLC. | $240.51 | 2023-2025 | Arexvy, Shingrix, Bexsero |
| Xeris Pharmaceuticals, INC. | $212.04 | 2022-2025 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $180.60 | 2022-2025 | Airsupra, Breztri, Flumist Quadrivalent |
| Idorsia Pharmaceuticals US INC | $179.66 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $165.79 | 2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $143.83 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $142.66 | 2024-2025 | |
| Novo Nordisk INC | $141.68 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $141.56 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $137.49 | 2020-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Antares Pharma, INC. | $132.78 | 2024-2025 | Xyosted |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.36 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $109.57 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Vanda Pharmaceuticals INC. | $98.24 | 2022-2025 | Fanapt |
| Phathom Pharmaceuticals, INC. | $63.79 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.19 | 2024-2025 | Caplyta |
| Dynavax Technologies Corporation | $37.50 | 2022-2024 | Heplisav-B |
| Insulet Corporation | $34.84 | 2025 | Omnipod |
| Teva Pharmaceuticals USA, INC. | $26.65 | 2024 | Ajovy |
| Dexcom, INC. | $24.20 | 2024 | Dexcom G6 Transmitter |
| Tris Pharma INC | $20.42 | 2025 | Dyanavel Xr |
| Biogen, INC. | $18.27 | 2023 | Spinraza |
| Viiv Healthcare Company | $16.78 | 2023 | Apretude |
| Corium, LLC | $15.04 | 2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $15.03 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Cloyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.